A stock purchase agreement outlines the sale of company stock to buyers. Here's how to create a stock purchase agreement, ...

Structure Therapeutics stock declined sharply due to some data it published. The data show that its flagship drug candidate appears to be safe and effective. The issue is that Eli Lilly's competing ...

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader. There's still plenty of work left to do ...

Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron.